The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Open accessAbstract
There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,790
High-performance lithium battery anodes using silicon nanowires
Chan, C. K., Peng, H., Liu, G., McIlwrath, K., Zhang, X. F., Huggins, R. A., & Cui, Y. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2007.411 · Cited by 6,683
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,517
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Applications of nanotechnology in water and wastewater treatment
Qu, X., Alvarez, P. J. J., & Li, Q. (2013) · Water Research · doi:10.1016/j.watres.2012.09.058 · Cited by 2,444
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Semiconductor Nanocrystals: Structure, Properties, and Band Gap Engineering
Smith, A. M., & Nie, S. (2010) · Accounts of Chemical Research · doi:10.1021/ar9001069 · Cited by 1,942
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Self-citationPrabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Strong, Light, Multifunctional Fibers of Carbon Nanotubes with Ultrahigh Conductivity
Behabtu, N., Young, C. C., Tsentalovich, D. E., Kleinerman, O., Wang, X., Ma, A. W. K., Bengio, E. A., ter Waarbeek, R. F., de Jong, J. J., Hoogerwerf, R. E., et al. (2013) · Science · doi:10.1126/science.1228061 · Cited by 1,354
ELSAYED, I., HUANG, X., & ELSAYED, M. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.035 · Cited by 1,354
Transformations of Nanomaterials in the Environment
Lowry, G. V., Gregory, K. B., Apte, S. C., & Lead, J. R. (2012) · Environmental Science & Technology · doi:10.1021/es300839e · Cited by 1,272
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Frey, N. A., Peng, S., Cheng, K., & Sun, S. (2009) · Chemical Society Reviews · doi:10.1039/b815548h · Cited by 1,200
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Gold nanoparticles as novel agents for cancer therapy
Jain, S., Hirst, D. G., & O'Sullivan, J. M. (2012) · The British Journal of Radiology · doi:10.1259/bjr/59448833 · Cited by 1,059
Nanosizing — Oral formulation development and biopharmaceutical evaluation
Kesisoglou, F., Panmai, S., & Wu, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.003 · Cited by 1,055
Nanocrystal technology, drug delivery and clinical applications
Müller, R., & Junghanns (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s595 · Cited by 953
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Effective drug delivery by PEGylated drug conjugates
Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00180-1 · Cited by 869
Synthesis, Characterization, and Applications of Dendrimer-Encapsulated Nanoparticles
Scott, R. W. J., Wilson, O. M., & Crooks, R. M. (2005) · The Journal of Physical Chemistry B · doi:10.1021/jp0469665 · Cited by 866
Sheridan, W. P., Fox, R. M., Begley, C. G., Maher, D., McGrath, K. M., Begley, C. G., Juttner, C. A., To, L. B., Szer, J., & Mostyn, G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90795-5 · Cited by 857
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Mesoporous silica nanoparticles in target drug delivery system: A review
Bharti, C., Gulati, N., Nagaich, U., & Pal, A. (2015) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.160844 · Cited by 817
Nanomedicine: Developing smarter therapeutic and diagnostic modalities☆
FAROKHZAD, O., & LANGER, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.011 · Cited by 800
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y.-S., Gatley, S. J., Gifford, A., & Franceschi, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0001.2001 · Cited by 770
There’s plenty of room at the bottom
Feynman, R. P. (2011) · Resonance · doi:10.1007/s12045-011-0109-x · Cited by 762
Shegokar, R., & Müller, R. H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.044 · Cited by 740
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
Polymeric nanoparticles for targeted drug delivery system for cancer therapy
Masood, F. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2015.11.067 · Cited by 702
Polymeric nanoparticles: A study on the preparation variables and characterization methods
Crucho, C. I. C., & Barros, M. T. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.06.004 · Cited by 696
Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
Bone Cell Proliferation on Carbon Nanotubes
Zanello, L. P., Zhao, B., Hu, H., & Haddon, R. C. (2006) · Nano Letters · doi:10.1021/nl051861e · Cited by 654
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
van der Lely, A. J., Hutson, R. K., Trainer, P. J., Besser, G. M., Barkan, A. L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06844-1 · Cited by 645
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Potential scenarios for nanomaterial release and subsequent alteration in the environment
Nowack, B., Ranville, J. F., Diamond, S., Gallego-Urrea, J. A., Metcalfe, C., Rose, J., Horne, N., Koelmans, A. A., & Klaine, S. J. (2012) · Environmental Toxicology and Chemistry · doi:10.1002/etc.726 · Cited by 598
Synthetic biodegradable functional polymers for tissue engineering: a brief review
Guo, B., & Ma, P. X. (2014) · Science China Chemistry · doi:10.1007/s11426-014-5086-y · Cited by 592
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Tadic, D., & Epple, M. (2004) · Biomaterials · doi:10.1016/s0142-9612(03)00621-5 · Cited by 550
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Facing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 527
Nanotechnology and its Applications in Medicine
Nikalje, A. P. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000247 · Cited by 512
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
Glue, P. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110973 · Cited by 504
The mammalian tachykinin receptors
Maggi, C. A. (1995) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(94)00292-u · Cited by 486
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
Landewé, R., Braun, J., Deodhar, A. A., Dougados, M., Maksymowych, W. P., Mease, P. J., Reveille, J. D., Rudwaleit, M., van der Heijde, D. M. F. M., Stach, C. M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204231 · Cited by 470
Liposome-based drug delivery in breast cancer treatment
Park, J. W. (2002) · Breast Cancer Research · doi:10.1186/bcr432 · Cited by 469
The history of attention deficit hyperactivity disorder
Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., & Tucha, O. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0045-8 · Cited by 446
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Smart Nanostructures for Cargo Delivery: Uncaging and Activating by Light
Karimi, M., Sahandi Zangabad, P., Baghaee-Ravari, S., Ghazadeh, M., Mirshekari, H., & Hamblin, M. R. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08313 · Cited by 421
Self-citationDrug discovery beyond the ‘rule-of-five’
Zhang, M.-Q., & Wilkinson, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.005 · Cited by 418
Martins, S., Sarmento, B. F. C. C., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 399
Engineered nanoparticles as precise drug delivery systems
Yih, T. C., & Al‐Fandi, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20796 · Cited by 392
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice
BarathManiKanth, S., Kalishwaralal, K., Sriram, M., Pandian, S. R. K., Youn, H.-S., Eom, S., & Gurunathan, S. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-16 · Cited by 386
Stephan, J. L., Vlekova, V., Deist, F. L., Blanche, S., Donadieu, J., Saint-Basile, G. D., Durandy, A., Griscelli, C., & Fischer, A. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80951-5 · Cited by 344
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
pH ‐Sensitive stimulus‐responsive nanocarriers for targeted delivery of therapeutic agents
Karimi, M., Eslami, M., Sahandi‐Zangabad, P., Mirab, F., Farajisafiloo, N., Shafaei, Z., Ghosh, D., Bozorgomid, M., Dashkhaneh, F., & Hamblin, M. R. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1389 · Cited by 327
Self-citationBalakumar, K., Raghavan, C. V., selvan, N. T., prasad, R. H., & Abdu, S. (2013) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.08.025 · Cited by 324
Liao, Y., Chang, Y., Yoshiike, Y., Chang, Y., & Chen, Y. (2012) · Small · doi:10.1002/smll.201201068 · Cited by 324
Pegaspargase: a review of clinical studies
Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322
The $2.6 Billion Pill — Methodologic and Policy Considerations
Avorn, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500848 · Cited by 318
Nanostructured polymer scaffolds for tissue engineering and regenerative medicine
Smith, I. O., Liu, X. H., Smith, L. A., & Ma, P. X. (2009) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.26 · Cited by 314
Doxorubicin in sterically stabilized liposomes
Lasic, D. D. (1996) · Nature · doi:10.1038/380561a0 · Cited by 308
Jacobson, I. M., Brown, R. S., Freilich, B., Afdhal, N., Kwo, P. Y., Santoro, J., Becker, S., Wakil, A. E., Pound, D., Godofsky, E., et al. (2007) · Hepatology · doi:10.1002/hep.21932 · Cited by 304
Slatopolsky, E. A., Burke, S. K., & Dillon, M. A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00240.x · Cited by 302
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
Modern Applications of Nanotechnology in Textiles
Sawhney, A. P. S., Condon, B., Singh, K. V., Pang, S. S., Li, G., & Hui, D. (2008) · Textile Research Journal · doi:10.1177/0040517508091066 · Cited by 291
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Pros and Cons of the Liposome Platform in Cancer Drug Targeting
Gabizon, A. A., Shmeeda, H., & Zalipsky, S. (2006) · Journal of Liposome Research · doi:10.1080/08982100600848769 · Cited by 272
Konkle, B. A., Stasyshyn, O., Chowdary, P., Bevan, D. H., Mant, T., Shima, M., Engl, W., Dyck-Jones, J., Fuerlinger, M., Patrone, L., et al. (2015) · Blood · doi:10.1182/blood-2015-03-630897 · Cited by 262
PEGylated polymers for medicine: from conjugation to self-assembled systems
Joralemon, M. J., McRae, S., & Emrick, T. (2010) · Chemical Communications · doi:10.1039/b920570p · Cited by 251
Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238
A lipid based depot (DepoFoam® technology) for sustained release drug delivery
Mantripragada, S. (2002) · Progress in Lipid Research · doi:10.1016/s0163-7827(02)00004-8 · Cited by 221
Hollis, C. P., Weiss, H. L., Leggas, M., Evers, B. M., Gemeinhart, R. A., & Li, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.06.039 · Cited by 204
Arnon, R., & Aharoni, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404887101 · Cited by 201
Onivyde for the therapy of multiple solid tumors
Zhang, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105587 · Cited by 187
Gary-Bobo, M., Hocine, O., Brevet, D., Maynadier, M., Raehm, L., Richeter, S., Charasson, V., Loock, B., Morère, A., Maillard, P., et al. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.11.045 · Cited by 186
Wang, J., Mongayt, D., & Torchilin, V. P. (2005) · Journal of Drug Targeting · doi:10.1080/10611860400011935 · Cited by 183
Eligard: leuprolide acetate in a novel sustained-release delivery system
Sartor, O. (2003) · Urology · doi:10.1016/s0090-4295(02)02396-8 · Cited by 183
Quantum dots – Nano-sized probes for the exploration of cellular and intracellular targeting
Hild, W. A., Breunig, M., & Goepferich, A. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.06.009 · Cited by 182
Impact of public and private research funding on scientific production: The case of nanotechnology
Beaudry, C., & Allaoui, S. (2012) · Research Policy · doi:10.1016/j.respol.2012.03.022 · Cited by 175
Zangabad, P. S., Karimi, M., Mehdizadeh, F., Malekzad, H., Ghasemi, A., Bahrami, S., Zare, H., Moghoofei, M., Hekmatmanesh, A., & Hamblin, M. R. (2016) · Nanoscale · doi:10.1039/c6nr07315h · Cited by 174
Self-citationThe Run on Ritalin: Attention Deficit Disorder and Stimulant Treatment in the 1990s
Diller, L. H. (1996) · The Hastings Center Report · doi:10.2307/3528571 · Cited by 172
Bressler, N. M. (2001) · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · Cited by 170
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
Murphy, T., & Yee, K. W. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1391216 · Cited by 169
Eetezadi, S., Ekdawi, S. N., & Allen, C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.001 · Cited by 166
Carbon Nanotubes as an Effective Opportunity for Cancer Diagnosis and Treatment
Sanginario, A., Miccoli, B., & Demarchi, D. (2017) · Biosensors · doi:10.3390/bios7010009 · Cited by 165
Smart Polymeric Nanoparticles for Cancer Gene Delivery
Lin, G., Zhang, H., & Huang, L. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500656v · Cited by 164
Polymer therapeutics: Top 10 selling pharmaceuticals — What next?
Duncan, R. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.001 · Cited by 161
Regulating Nanomedicine – Can the FDA Handle It?
Bawa, R. (2011) · Current Drug Delivery · doi:10.2174/156720111795256156 · Cited by 160
Takayama, N., Sato, N., O’Brien, S. G., Ikeda, Y., & Okamoto, S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03881.x · Cited by 159
Kraus, V. B., Conaghan, P. G., Aazami, H. A., Mehra, P., Kivitz, A., Lufkin, J., Hauben, J., Johnson, J. R., & Bodick, N. C. (2017) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2017.10.003 · Cited by 159
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
Kim, S., Chatelut, É., Kim, J. C., Howell, S. B., Cates, C., Kormanik, P. A., & Chamberlain, M. C. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2186 · Cited by 157
Ige, P. P., Baria, R. K., & Gattani, S. G. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.02.043 · Cited by 156
Yarmolenko, P., Zhao, Y., Landon, C. D., Spasojević, I., Yuan, F., Needham, D., Viglianti, B. L., & Dewhirst, M. W. (2010) · International Journal of Hyperthermia · doi:10.3109/02656731003789284 · Cited by 154
Development of aptamer therapeutics
Bunka, D. H. J., Platonova, O., & Stockley, P. G. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.009 · Cited by 153
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
Passero, F. C., Grapsa, D., Syrigos, K., & Saif, M. W. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192471 · Cited by 152
Lin, J., Liu, Z.-K., Zhu, Q., Rong, X.-H., Liang, C.-L., Wang, J., Ma, D., Sun, J., & Wang, G.-H. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.04.002 · Cited by 147
Steele, M. M., Weiss, M. D., Swanson, J. M., Wang, J., Prinzo, R., & Binder, C. E. (2006) · PubMed · Cited by 145
Revisiting Crohn's disease as a primary immunodeficiency of macrophages
Casanova, J., & Abel, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20091683 · Cited by 142
Wu, Z., Wu, Z., Tang, H., Tang, L., & Jiang, J. (2013) · Analytical Chemistry · doi:10.1021/ac303575f · Cited by 139
Schwenk, M. H. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.1.70 · Cited by 136
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
Fassas, Α., & Anagnostopoulos, Α. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500052438 · Cited by 134
Intra-articular drug delivery systems for joint diseases
Rai, M. F., & Pham, C. T. N. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.013 · Cited by 132
Recent trends of nanomedicinal approaches in clinics
Dilnawaz, F., Acharya, S., & Sahoo, S. K. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.01.016 · Cited by 129
Mechanism of Action of Glatiramer Acetate in Treatment of Multiple Sclerosis
Weber, M. S., Hohlfeld, R., & Zamvil, S. S. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.08.002 · Cited by 127
Boman, N. L., Masin, D., Mayer, L. D., Cullis, P. R., & Bally, M. B. (1994) · PubMed · Cited by 126
Farjadian, F., Moghoofei, M., Mirkiani, S., Ghasemi, A., Rabiee, N., Hadifar, S., Ali Beyzavi, B., Karimi, M., & Hamblin, M. R. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.02.016 · Cited by 126
Self-citationAdverse Side Effects of Methylphenidate among Mentally Retarded Children with ADHD
Handen, B. L., Feldman, H. M., GOSLING, A., Breaux, A. M., & McAuliffe, S. (1991) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199103000-00012 · Cited by 125
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1504317 · Cited by 125
Challenges of clinical translation in nanomedicine: A qualitative study
Satalkar, P., Elger, B. S., Hunziker, P., & Shaw, D. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.12.376 · Cited by 124
Roman, J. A., Niedzielko, T. L., Haddon, R. C., Parpura, V., & Floyd, C. L. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1409 · Cited by 123
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122
Advances and innovations in haemophilia treatment
Peters, R., & Harris, T. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.70 · Cited by 122
Path-breaking directions of nanotechnology-based chemotherapy and molecular cancer therapy
Coccia, M., & Wang, L. (2014) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2014.09.007 · Cited by 122
Transdermal delivery of a pineal hormone: Melatonin via elastic liposomes
Dubey, V., Mishra, D. K., Asthana, A., & Jain, N. K. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.01.060 · Cited by 120
Smart mesoporous silica nanoparticles for controlled-release drug delivery
Karimi, M., Mirshekari, H., Aliakbari, M., Zangabad, P. S., & Hamblin, M. R. (2015) · Nanotechnology Reviews · doi:10.1515/ntrev-2015-0057 · Cited by 119
Self-citationThe Valley of Death in anticancer drug development: a reassessment
Adams, D. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.001 · Cited by 118
Formulation of Neulasta® (pegfilgrastim)
Piedmonte, D. M., & Treuheit, M. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.017 · Cited by 117
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss, F. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.017 · Cited by 116
Omics-based nanomedicine: The future of personalized oncology
Rosenblum, D., & Peer, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.029 · Cited by 114
Spivak, M. Y., Bubnov, R. V., Yemets, I. M., Lazarenko, L. M., Tymoshok, N. O., & Ulberg, Z. R. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-20 · Cited by 114
Jaeckle, K. A., Batchelor, T. T., O'Day, S. J., Phuphanich, S., New, P., Lesser, G. J., Cohn, A. L., Gilbert, M. R., Aiken, R. D., Heros, D. O., et al. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1015752331041 · Cited by 113
Nanopharmaceuticals (part 2): products in the pipeline
Weissig, V., & Guzman‐Villanueva, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s65526 · Cited by 113
Landry, R., Jacobs, P. M., Davis, R., Shenouda, M., & Bolton, W. K. (2005) · American Journal of Nephrology · doi:10.1159/000087212 · Cited by 108
Reshaping the Future of Nanopharmaceuticals: Ad Iudicium
Moghimi, S. M., Peer, D., & Langer, R. (2011) · ACS Nano · doi:10.1021/nn2038252 · Cited by 105
Prajapati, R. N., Tekade, R. K., Gupta, U. D., et al. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002489 · Cited by 104
The Thalidomide Disaster, Lessons from the Past
Ridings, J. E. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-131-8_36 · Cited by 100
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease
Coyne, D. W. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903224998 · Cited by 95
Magnetic nanoparticles: Applications in gene delivery and gene therapy
Majidi, S., Sehrig, F. Z., Samiei, M., Milani, M., Abbasi, E., Dadashzadeh, K., & Akbarzadeh, A. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1014093 · Cited by 95
Clemons, K. V., & Stevens, D. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1047-1050.2004 · Cited by 87
Thomas, D. A., Sarris, A. H., Cortes, J. E., Faderl, S. H., O'Brien, S. M., Giles, F. J., Garcia‐Manero, G., Rodriguez, M. A., Cabanillas, F., & Kantarjian, H. M. (2005) · Cancer · doi:10.1002/cncr.21595 · Cited by 86
Andreopoulou, E., Gaiotti, D., Kim, E., Downey, A., Mirchandani, D., Hamilton, A., Jacobs, A., Curtin, J. P., & Muggia, F. M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl484 · Cited by 85
Methotrexate delivery via folate targeted dendrimer‐based nanotherapeutic platform
Majoros, I., WILLIAMS, C. R., Becker, A., & Baker, J. R. (2009) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.37 · Cited by 83
Nanotechnology in Diagnosis and Treatment of Coronary Artery Disease
Karimi, M., Zare, H., Nik, A. B., Yazdani, N., Hamrang, M., Mohamed, E., Zangabad, P. S., Basri, S. M. M., Bakhtiari, L., & Hamblin, M. R. (2016) · Nanomedicine · doi:10.2217/nnm.16.3 · Cited by 83
Self-citationFrom lab to market? Strategies and issues in the commercialization of nanotechnology in China
Philip Shapira, A., & Wang, J. (2009) · Asian Business & Management · doi:10.1057/abm.2009.15 · Cited by 82
SMART drug delivery systems: Back to the future vs. clinical reality
Lammers, T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.046 · Cited by 80
Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Iyer, R., Hsia, C. C. W., & Nguyen, K. T. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150923095742 · Cited by 80
Liu, L., Ye, Q., Lu, M., Lo, Y.-C., Hsu, Y., Wei, M.-C., Chen, Y.-H., Lo, S., Wang, S.-J., Bain, D. J., et al. (2015) · Scientific Reports · doi:10.1038/srep10881 · Cited by 78
The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients
Spinowitz, B., Schwenk, M. H., Jacobs, P. M., Bolton, W. K., Kaplan, M. R., Charytan, C., & Galler, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00598.x · Cited by 74
Cancer nanomedicines: closing the translational gap
Gabizón, A., Bradbury, M. S., Prabhakar, U., Zamboni, W. C., Libutti, S. K., & Grodzinski, P. A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61457-4 · Cited by 73
Drug delivery systems for hormone therapy
Yoo, J.-W., & Lee, C. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.021 · Cited by 72
Pillai, G., & Ceballos-Coronel, M. L. (2013) · SAGE Open Medicine · doi:10.1177/2050312113513759 · Cited by 71
Carbon nanotubes as vaccine scaffolds
Scheinberg, D. A., McDevitt, M. R., Dao, T., Mulvey, J. J., Feinberg, E. N., & Alidori, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.013 · Cited by 71
Parmentier, J., Hofhaus, G., Thomas, S., Clusa, L., Gropp, F., Schröder, R. R., Hartmann, K., & Fricker, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24215 · Cited by 71
Estradiol in micellar nanoparticles
Simon, J. A. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000174096.56652.4f · Cited by 70
Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults
Rogers, A. H., Duker, J. S., Nichols, N., & Baker, B. J. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00466-4 · Cited by 70
Development of a DNA-liposome complex for gene delivery applications
Rasoulianboroujeni, M., Kupgan, G., Moghadam, F., Tahriri, M., Boughdachi, A., Khoshkenar, P., Ambrose, J. J., Kiaie, N., Vashaee, D., Ramsey, J. D., et al. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.02.012 · Cited by 70
The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT1A receptor
Markowitz, J. S., Markowitz, J. S., DeVane, C. L., Ramamoorthy, S., Zhu, H.-J., & Zhu, H.-J. (2009) · Die Pharmazie · doi:10.31083/ph.2009.8691 · Cited by 68
Lipid-based formulations of amphotericin B
Veerareddy, P. R., & Vobalaboina, V. (2004) · Drugs of today · doi:10.1358/dot.2004.40.2.799425 · Cited by 68
Bankruptcy filing worries developers of nanoparticle cancer drugs
Ledford, H. K. (2016) · Nature · doi:10.1038/533304a · Cited by 65
Langer, R., & Weissleder, R. (2015) · JAMA · doi:10.1001/jama.2014.16315 · Cited by 65
McCormack, P. L. (2012) · Drugs · doi:10.2165/11209880-000000000-00000 · Cited by 64
Are RNAi and miRNA therapeutics truly dead?
Conde, J., & Artzi, N. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.12.005 · Cited by 63
A Magnetic Nanoparticle-Based Multiple-Gene Delivery System for Transfection of Porcine Kidney Cells
Wang, Y., Cui, H., Li, K., Sun, C., Du, W., Cui, J., Zhao, X., & Chen, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102886 · Cited by 62
How Should We Do Nanoethics? A Network Approach for Discerning Ethical Issues in Nanotechnology
van de Poel, I. (2008) · NanoEthics · doi:10.1007/s11569-008-0026-y · Cited by 62
Stimuli-Responsive Gold Nanoparticles for Cancer Diagnosis and Therapy
Li, T. X., Lu, L., Qiao, Y., Ravi, S., Salatan, F., & Melancon, M. P. (2016) · Journal of Functional Biomaterials · doi:10.3390/jfb7030019 · Cited by 62
Reiner, A. T., Ferrer, N.-G., Venugopalan, P., Lai, R. C., Lim, S. K., & Dostálek, J. (2017) · The Analyst · doi:10.1039/c7an00469a · Cited by 60
Solubility enhancement of paclitaxel using a linear-dendritic block copolymer
Zhou, Z., D’Emanuele, A., & Attwood, D. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.075 · Cited by 58
Wang, J. T.-W., Rubio, N., Kafa, H., Venturelli, E., Fabbro, C., Ménard‐Moyon, C., Ros, T. D., Sosabowski, J. K., Lawson, A. D. G., Robinson, M. K., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.039 · Cited by 55
Hydroxyl-modified magnetite nanoparticles as novel carrier for delivery of methotrexate
Farjadian, F., Ghasemi, S., & Mohammadi‐Samani, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.022 · Cited by 55
Self-citationLee, R. W., Shenoy, D. B., & Sheel, R. (2009) · Elsevier eBooks · doi:10.1016/b978-0-8155-2025-2.10002-2 · Cited by 52
Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis
Johnson, K. P. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.25 · Cited by 52
Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate
Abdel-Salam, F. S., Mahmoud, A. A. K., Ammar, H. O., & Elkheshen, S. A. (2016) · Journal of Liposome Research · doi:10.3109/08982104.2016.1149866 · Cited by 51
FDA and Nanotech: Baby Steps Lead to Regulatory Uncertainty
Bawa, R. (2013) · Wiley eBooks · doi:10.1002/9781118451915.ch41 · Cited by 50
Narayan, R., Pednekar, A., Bhuyan, D., Gowda, C., Koteshwara, K. B., & Nayak, U. Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s141504 · Cited by 49
Past, Present and Future Targets For Immunotherapy in Ovarian Cancer
Schwab, C. L., English, D. P.-G., Roque, D. M., Pasternak, M. C., & Santin, A. D. (2014) · Immunotherapy · doi:10.2217/imt.14.90 · Cited by 47
Sun, L., Deng, X., Yang, X., Li, Z., Wang, Z., Li, L., Wu, Q., Peng, F., Liu, L., & Gong, C. (2014) · RSC Advances · doi:10.1039/c4ra07453j · Cited by 46
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
Yang, S., Lin, C., Lin, Z., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9522-3 · Cited by 43
Alagona, P. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6714 · Cited by 42
Farjadian, F., Ahmadpour, P., Mohammadi‐Samani, S., & Hosseini, M. H. (2015) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2015.04.002 · Cited by 41
Self-citationEthical issues in nanomedicine: Tempest in a teapot?
Allon, I., Ben‐Yehudah, A., Dekel, R., Solbakk, J. H., Weltring, K., & Siegal, G. (2016) · Medicine Health Care and Philosophy · doi:10.1007/s11019-016-9720-7 · Cited by 40
Wex, J., Sidhu, Odeyemi, Abou-Setta, Retsa, & TOMBAL, B. F. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s44855 · Cited by 39
Farjadian, F., Moradi, S., & Hosseini, M. H. (2017) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-017-5854-2 · Cited by 39
Self-citationCOX-2 Inhibition: What We Learned—A Controversial Update on Safety Data
Katz, J. A. (2013) · Pain Medicine · doi:10.1111/pme.12252 · Cited by 38
Evaluation and Treatment of CKD Patients Before and at Their First Nephrologist Encounter in Canada
Curtis, B. M., Barrett, B. J., Djurdjev, O., Singer, J., & Levin, A. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.08.004 · Cited by 38
Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability
Berges, R. R. (2005) · European Urology Supplements · doi:10.1016/j.eursup.2005.04.001 · Cited by 38
Poly(lactic- co -glycolic acid): The most ardent and flexible candidate in biomedicine!
Roointan, A., Kianpour, S., Memari, F., Gandomani, M., Hayat, S. M. G., & Mohammadi‐Samani, S. (2018) · International Journal of Polymeric Materials · doi:10.1080/00914037.2017.1405350 · Cited by 38
Self-citation
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Biocompatibility of nanomaterials and their immunological properties
Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, R., Mohammed, F. S., Halder, S., Xu, M., Wu, M. J., Bao, S., et al. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe5fa · Cited by 389
Overcoming barriers by local drug delivery with liposomes
Antimisiaris, S. G., Marazioti, A., Kannavou, M., Natsaridis, E., Gkartziou, F., Kogkos, G., & Mourtas, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.019 · Cited by 339
Metadata
- Authors
- Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-11-19
- Volume
- 14
- Issue
- 1
- Pages
- 93-126
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2901675852
- Cited by
- 664
- References
- 233
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.